Synthesis, structure-activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics

Journal of Medicinal Chemistry

Volumn 49, Issue 21, 2006, Pages 6343-6350

  Easmon, Johnny ^a   Pürstinger, Gerhard ^a   Thies, Katrin Sofia ^a   Heinisch, Gottfried ^a   Hofmann, Johann ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 ACETYLPYRIDINE; 2 ACYLPYRIDINE; 2 BENZOXAZOLYL HYDRAZONE; ALPHA ACETYLDIAZINE; HETEROCYCLIC COMPOUND; HYDRAZONE DERIVATIVE; N BENZOAZOL 2 YL N' (1 ISOQUINOLIN 3 YL ETHYLIDENE)HYDRAZINE; OROSOMUCOID; PICOLINALDEHYDE; QUINOLINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CANCER CELL CULTURE; CELL KILLING; CELL PROLIFERATION; CELL STRAIN HT29; CELL STRAIN MCF 7; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HOLLOW FIBER; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; LYMPHOMA CELL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THIN LAYER CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS; BENZOXAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDRAZONES; ORGAN SPECIFICITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750120498     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060232u     Document Type: Article

References (44)

1. Grever, M. R.; Chabner, B. A. Cancer drug discovery and development. In Cancer. Principles and Practice of Oncology; DeVita, V. T., Jr., Hellman, S., Rosenberg, S. A., Eds.; J. B. Lipincott Company: New York, 1997; pp 385-394.
2. Mauro, M. J.; O'Dwyer, M.; Heinrich, M. C.; Druker, B. J. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 2002, 20, 325-334.
3. Elledge, S. J.; Zhou, Z.; Allen, J. B. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem. Sci. 1992, 17, 119-123.
4. Engström, Y.; Eriksson, S.; Thealander, L.; Äkerman, M. Ribonucleotide reductase from calf thymus: purification and properties. Biochemistry 1979, 18, 2941-2948.
5. Thealander, L.; Eriksson, S.; Äkerman, M. Ribonucleotide reductase from calf thymus. Separation of the enzyme into nonidentical subunits, proteions M1 and M2. J. Biol. Chem. 1980, 257, 5711-5715.
6. Fox, R. M. Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase. In Inhibitors of Ribonucleotide Reductase Activity; Cory, J. G., Cory, A. H., Eds.; Pergamon Press: Oxford, 1989; pp 113-125.
7. Yvan, G.; Lavallée, P.; Rakhit, S.; Cosentino, G. P. Ribonucleotide reductase inhibitors. EP 0383190 (Bio-mega, Inc.), 1990.
8. Agrawal, K. C.; Sartorelli, A. C. The chemistry and biological activity of alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog. Med. Chem. 1978, 15, 321-356.
9. Cory, J. G.; Downes, D. L.; Cory, A. H.; Schaper, K.-J.; Seydel, J. K. Substituted 2-acylpyridine-α-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth. Anticancer Res. 1994, 14, 875-880.
10. Easmon, J.; Heinisch, G.; Hofmann, J.; Langer, T.; Grunicke, H. H.; Fink, J.; Ptirstinger, G. Thiazolyl and benzothiazolyl hydrazones derived from α-(N)-acetylpyridines and diazines: synthesis, antiproliferative activity and CoMFA studies. Eur. J. Med. Chem. 1997, 32, 397-408.
11. Hall, I. H.; Peaty, N. J.; Henry, J. R.; Easmon, J.; Heinisch, G.; Piirstinger, G. Investigations on the mechanism of action of the novel antitumor agents 2-benzothiozolyl, 2-benzoxazolyl, and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine. Arch. Pharm. Pharm. Med. Chem. 1999, 33, 115-123.
12. Easmon, J.; Puerstinger, G.; Roth, T.; Fiebig, H. H.; Jenny, M.; Jaeger, W.; Heinisch, G.; Hofmann, J. 2-Benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: a novel class of antitumor agents. Int. J. Cancer 2001, 94, 89-96.
13. Katz, L. Antituberculous compounds, III. Benzothiazole and benzoxazole derivatives. J. Am. Chem. Soc. 1953, 75, 712-714.
14. Nagarajan, K.; Kulkarni, C. L.; Shah, R. K. Novel dealkylating and deaminating reactions of 2-chlorbenzothiazole, 2-chlorbenzoxzole, 2-chloropyridine, and methyl 2-chloro-5-nitrobenzoate with N-amino-compounds. Indian J. Chem. 1971, 9, 748-754.
15. Scovill, J. P.; Klayman, D. L.; Lambros, C.; Childs, G. E.; Notsch, D. 2-Acetylpyridine thiosemicarbazones. 9. Derivatives of 2-acetylpyridine 1-oxide as potential antimalarial agents. J. Med. Chem. 1984, 27, 87-91.
16. Knebel, N. G.; von Angerer, E. 2-Phenylindole-linked [2-(aminoalky-1) pyridine]dichloroplatin(II): Complexes with a selective action on estrogen receptor positive mammary tumors. J. Med. Chem. 1991, 34, 2145-2152.
17. Prathapan, S.; Robinson, K. E.; Agosta, W. C. Triplet states mediating hydrogen abstraction in 4-acylpyrimidines, 2-acylpyridines, 2-a-cylpyrazines, and 3-acylpyridazines. J. Am. Chem. Soc. 1992, 114, 1838-1843.
18. Teauge, P. C.; Ballentine, A. R.; Rushton, G. L. Some pyridylhydantoins. J. Am. Chem. Soc. 1953, 75, 3429-3430.
19. Henze, H. R.; Knowles, M. B. Synthesis of 5-(pyridyl-substituted)- hydantoins. J. Org. Chem. 1954, 19, 9-1135.
20. McCartey, F. J.; Tilford, C. H.; van Campen, M. G., Jr.; Central stimulants. α,α-Disubstituted 2-piperidinemethanols and 1,1-disubstituted heptahydoöxazolo[3,4-a]pyridines. J. Am. Chem. Soc. 1957, 79, 472-480.
21. Case, F. H.; Butte, W. A. Further preparation of substituted 2,6-bis-(2′-pyridyl)pyridines. J. Org. Chem. 1961, 26, 4415-4418.
22. McCann, G.; O'Ferrall, R. A. M.; Walsh, S. M. Proton activating features and keto-enol-zwitterion tautomerism of 2-, 3-, and 4-phenylacetylpyridines. J. Chem. Soc., Perkin Trans. 2 1997, 2761-2772.
23. Antonioni, I.; Claudi, F.; Franchetti, P.; Griffantini, M.; Martelli, S. Elucidation of the structure of the antineoplastic agents, 2-formylpyridine and 1-formylisoquinoline thiosemicarbazones. J. Med. Chem. 1977, 20, 447-449.
24. Easmon, J.; Heinisch, G.; Holzer, W. Pyridazines 47. The configuration of novel thiosemicarbazone derivatives of pyridazinecarbaldehydes and aryl pyridazinyl ketones. Heterocycles 1989, 29, 1399-1408.
25. Boyd, M. R. Status of the NCI preclinical antitumor drug discovery screen. In Principles and practice of oncology updates; De Vita, V. T., Jr. Hellman, S., Rosenberg, S. A., Eds.; Lippincott: Philadelphia, PA, 1989: Vol. 3, pp 1-12.
26. See, http://dtp.nci.nih.gov/dtp.
27. Liscovitch, M.; Lavie, Y. Cancer multidrug resistance: A review of recent drug discovery research. 1Drugs 2002, 5, 345-355.
28. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discovery 2006, 5, 219-234.
29. Tillement, J. P.; Houin, G.; Urein, S.; Albengres, E.; Barre, J.; Lecomte, M.; D'Athis, P.; Sebille, B. The binding of drug to blood plasma macromolecules: Recent advances and therapeutic significance. Adv. Drug Res. 1984, 13, 60-96.
30. Fuse, E.; Tanii, H.; Kurata, N.; Kobayshi, H.; Shimada, Y.; Tamura, T.; Sasaki, Y.; Tanigawara, Y.; Lush, R. D.; Headlee, D.; Figg, W. D.; Arbuch, S. G.; Senderowicz, A. M.; Sausville, E. A.; Akinaga, S.; Kuwabara, T.; Kobayashi, S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 1998, 58, 3248-3253.
31. Hollinghead, M. G.; Alley, M. C.; Camalier, R. F.; Abbott, B. J.; Mayo, J. G.; Malspeis, L.; Grever, M. R. In vivo cultivation of tumorcells in hollow fibers. Life Sci. 1995, 57, 131-141.
32. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
33. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J., Jr.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L. V.; Anderson, L. N.; Boulamwini, J. K.; Van Osdal, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275, 343-349.
34. Easmon, J.; Heinisch, G.; Holzer, W.; Rosenwirth, B. Synthesis and antiviral activity of thiosemicarbazone derivatives of pyridazinecarbaldehydes and alkyl pyridazine ketones. Arzneim.-Forsch./Drug Res. 1989, 1196-1201.
35. Easmon, J.; Heinisch, G.; Holzer, W.; Rosenwirth, B. Novel thiosemicarbazones derived from formyl and acyldiazines: Synthesis, effects on cell proliferation, and synergism with antiviral agents. J. Med. Chem. 1992, 35, 3288-3296.
36. Batori, S.; Messmer, A. Synthesis of new v-triazolopyridinium salts. J. Heterocycl. Chem. 1994, 31, 1041-1046.
37. Sakamoto, T.; Sakasai, T.; Yamanaka, H. Studies on pyridine derivatives. XVI. Site selectivity in the homolytic substitution of simple pyrimidines. Chem. Pharm. Bull. 1980, 28, 571-577.
38. Schwaiger, W.; Cornelissen, J. M.; Ward, J. P. A. A convenient synthesis of alkyl- and arylpyrazinyl ketones. Food Chem. 1984, 13, 225-234.
39. Campbell, K. N.; Helbing, C. H.; Kerwin, J. F. Quinoline series. V. Preparation of some α-dialkylaminomethyl-2-quinolinemethanols. J. Am. Chem. Soc. 1946, 68, 1840-1843.
40. Klayman, D. L.; Acton, N.; Scovill, J. P. 2-Acetylpyridine thiosemicarbazones. 12. Derivatives of 3-acetylisoquinoline as potential antimalarial agents. Arzneim.-Forsch./Drug Res. 1986, 36, 10-13.
41. Spitaler, M.; Utz, I.; Hilbe, W.; Hofmann, J.; Grunicke, H. H. PKC-independent modulation of multidrug resistance in cells expressing mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin. Biochem. Pharmacol. 1998, 56, 861-869.
42. Bhalla, K.; Hindenburg, A.; Taub, R. N.; Grant, S. Isolation and characterization of an anthracyline-resistant human leukemic cell line. Cancer Res. 1985, 45, 3657-3662.
43. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
44. Mosman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.